Last update:

HIV & AIDS news

HIV & AIDS

Antibodies that recognize lipids: A new path for HIV vaccines and autoimmune disease treatments

Lipids are the fatty molecules that make up cellular membranes, creating a protective barrier that regulates what enters and exits the cell. Until recently, scientists believed antibodies couldn't safely target lipids without ...

HIV & AIDS

Genetic characteristics linked to long-term HIV remission after stopping treatment

Tackling HIV continues to be a major public health challenge, mainly because the persistence of viral reservoirs means that people living with HIV need to take lifelong antiretroviral treatment. But some individuals, known ...

HIV & AIDS

Unexpected hives reaction seen in trial of mRNA vax against HIV

A safety analysis of mRNA vaccination in a phase 1, randomized, open-label clinical trial evaluated the safety and tolerability of three investigational HIV-1 trimer mRNA vaccines. The study vaccines were found to be generally ...

HIV & AIDS

How a potential HIV cure may affect transmission

A mathematical modeling study coordinated by UMC Utrecht has shown that sustained HIV remission (without rebound) or HIV eradication cure scenarios could consistently reduce new HIV infections among men who have sex with ...

HIV & AIDS

Worm eradication: A surprising ally in the fight against HIV

Researchers from the Munich Tropical Institute, the Tanzanian NIMR-MMRC, DZIF, together with colleagues from Bonn, have discovered a risk factor for HIV infection that has received little attention to date. In an earlier ...

HIV & AIDS

New 'highly virulent' HIV strain discovered in the Netherlands

Oxford researchers announced Thursday the discovery of a highly virulent strain of HIV that has been lurking in the Netherlands for decades, but because of the effectiveness of modern treatments, is "no cause for alarm."

HIV & AIDS

Tracking cells that host HIV

New research sheds light on the lifespans and location of the cells that are responsible for producing HIV, preventing its eradication. Understanding the cells' dynamics may help scientists develop new ways to reduce their ...

Medications

Promising results of Phase 1 drug trial for HIV patients

A Phase 1 clinical trial conducted by University of Minnesota researchers has demonstrated the safety and efficacy of a novel immunotherapy drug in the treatment of human immunodeficiency virus (HIV). Results of the trial ...

Medications

Long-acting cabotegravir not necessarily cost-effective for PrEP

(HealthDay)—For men who have sex with men and transgender women (MSM/TGW) at very high risk for HIV (VHR), the benefits of long-acting injectable cabotegravir (CAB-LA) in terms of life expectancy do not necessarily justify ...

Oncology & Cancer

Study finds cancer immunotherapy treatment can reverse HIV latency

An international research collaboration has found the cancer immunotherapy treatment, pembrolizumab, can reverse HIV latency, the ability for the virus to 'hide' inside cells of people living with HIV on antiretroviral therapy, ...

HIV & AIDS

Men who paid for sex more likely than other men to live with HIV

Twenty years' worth of surveys suggest that nearly one in ten sexually active men in 35 countries in sub-Saharan Africa have been clients of sex workers, and these men are about 50 percent more likely to be living with human ...